Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3260877rdf:typepubmed:Citationlld:pubmed
pubmed-article:3260877lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:3260877lifeskim:mentionsumls-concept:C0242275lld:lifeskim
pubmed-article:3260877lifeskim:mentionsumls-concept:C0012472lld:lifeskim
pubmed-article:3260877lifeskim:mentionsumls-concept:C0039654lld:lifeskim
pubmed-article:3260877lifeskim:mentionsumls-concept:C0042305lld:lifeskim
pubmed-article:3260877lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:3260877lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:3260877pubmed:issue1-2lld:pubmed
pubmed-article:3260877pubmed:dateCreated1988-8-26lld:pubmed
pubmed-article:3260877pubmed:abstractTextThe cell line designated as A431 is characterized by an extraordinary capacity for binding of epidermal growth factor (EGF); but paradoxically, these cells also are characterized by failure of replication in response to treatment with EGF and other mitogens. In this study, we took advantage of this unique response of A431 cells to EGF and other mitogenic agents. Specifically, we investigated the dependency of mitogen-stimulated prostaglandin production on mitogenesis. The effects of treatment of A431 cells with epidermal growth factor and two other mitogenic agents, viz., sodium orthovanadate and 12-O-tetradecanoylphorbol-13-acetate (TPA), on DNA synthesis and prostaglandin production were evaluated. The rate of prostaglandin production in A431 cells that were treated with each of these agents increased in a manner that was dependent upon the duration of treatment and the concentration of the agent tested. Thus, by use of A431 cells, we find that the effects of 'mitogenic' agents on cell replication and prostaglandin production are clearly dissociable.lld:pubmed
pubmed-article:3260877pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3260877pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3260877pubmed:languageenglld:pubmed
pubmed-article:3260877pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3260877pubmed:citationSubsetIMlld:pubmed
pubmed-article:3260877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3260877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3260877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3260877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3260877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3260877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3260877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3260877pubmed:statusMEDLINElld:pubmed
pubmed-article:3260877pubmed:monthMaylld:pubmed
pubmed-article:3260877pubmed:issn0303-7207lld:pubmed
pubmed-article:3260877pubmed:authorpubmed-author:MilewichLLlld:pubmed
pubmed-article:3260877pubmed:authorpubmed-author:MacDonaldP...lld:pubmed
pubmed-article:3260877pubmed:authorpubmed-author:CaseyM LMLlld:pubmed
pubmed-article:3260877pubmed:authorpubmed-author:BerchuckAAlld:pubmed
pubmed-article:3260877pubmed:issnTypePrintlld:pubmed
pubmed-article:3260877pubmed:volume57lld:pubmed
pubmed-article:3260877pubmed:ownerNLMlld:pubmed
pubmed-article:3260877pubmed:authorsCompleteYlld:pubmed
pubmed-article:3260877pubmed:pagination87-92lld:pubmed
pubmed-article:3260877pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3260877pubmed:meshHeadingpubmed-meshheading:3260877-...lld:pubmed
pubmed-article:3260877pubmed:meshHeadingpubmed-meshheading:3260877-...lld:pubmed
pubmed-article:3260877pubmed:meshHeadingpubmed-meshheading:3260877-...lld:pubmed
pubmed-article:3260877pubmed:meshHeadingpubmed-meshheading:3260877-...lld:pubmed
pubmed-article:3260877pubmed:meshHeadingpubmed-meshheading:3260877-...lld:pubmed
pubmed-article:3260877pubmed:meshHeadingpubmed-meshheading:3260877-...lld:pubmed
pubmed-article:3260877pubmed:meshHeadingpubmed-meshheading:3260877-...lld:pubmed
pubmed-article:3260877pubmed:meshHeadingpubmed-meshheading:3260877-...lld:pubmed
pubmed-article:3260877pubmed:meshHeadingpubmed-meshheading:3260877-...lld:pubmed
pubmed-article:3260877pubmed:meshHeadingpubmed-meshheading:3260877-...lld:pubmed
pubmed-article:3260877pubmed:year1988lld:pubmed
pubmed-article:3260877pubmed:articleTitleEpidermal growth factor, vanadate, and 12-O-tetradecanoylphorbol-13-acetate inhibit growth and stimulate prostaglandin E2 production in A431 cells.lld:pubmed
pubmed-article:3260877pubmed:affiliationCecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical School, Dallas 75235.lld:pubmed
pubmed-article:3260877pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3260877pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed